Home » Drug Information » FDA-Approved Drugs » 1997
Medical Areas: Dermatology/Plastic Surgery
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: SmithKline Beecham
Approval Status: Approved December 1997
Treatment Area: secondarily infected traumatic skin lesions
Bactroban Cream (mupirocin calcium cream, 2%) has been approved
as a topical antibiotic treatment for secondarily infected
traumatic skin lesions. Bactroban Cream will be available in 15
gram and 30 gram tubes. Bactroban Cream should be applied to the
affected area three times daily for 10 days.
In two randomized, double-blind clinical trials, Bactroban Cream
demonstrated equivalent efficacy to the oral cephalosporin
antibiotic Keflex. Clinical efficacy rates at follow-up were 96.1%
for Bactroban Cream and 93.9% for oral Keflex.
There is virtually no risk of systemic side effects or drug
interactions due to Bactroban Cream. The most common side effects
reported include headache, rash and nausea.